(CercleFinance.com) – MaaT Pharma announced on Tuesday that it had completed the recruitment of patients in its Phase 2a clinical trial evaluating MaaT013, its most advanced drug candidate, in melanoma.
A total of 70 patients were recruited in five different centers in France as part of this randomized controlled trial which began in April 2022.
Sponsored by AP-HP and conducted in collaboration with Inrae and the Gustave Roussy Institute, the trial aims to evaluate the effectiveness of the compound with the immune checkpoint inhibitors Yervoy and Opdivo, owned by the American Bristol Myers Squibb.
As part of the study, the pharmaceutical company provided the drug candidate MaaT013 and the placebo and will carry out analyzes of the patients’ microbiota using its proprietary ‘gutPrint’ platform.
After this key stage, submission of the study results to a scientific journal is planned for the last quarter of 2024 or the first quarter of 2025.